Why Novocure stock is up today? By Investing.com
[ad_1]
© Reuters. Why Novocure stock is up today?
NovoCure (NASDAQ:) experienced a notable increase in its stock price, jumping up around 13% intra-day today, marking its highest point since Oct 19. This boost is attributed to Novocure’s confirmation of its attendance at the upcoming JPMorgan healthcare investor conference next month. William Doyle, the Executive Chairman of Novocure, is scheduled to present on behalf of the company on Jan 10.
Earlier this month, Piper Sandler highlighted Novocure as one of the companies expected to share insights into their fourth-quarter performance at this annual health event. This expectation stems from Novocure’s history of providing such details in previous years.
Novocure, the maker of a wearable cancer-targeting therapy known as TTFields, announced last month a workforce reduction of 13%. Despite this, the company maintains its readiness for the potential approval of its treatment for metastatic non-small cell lung cancer after progression on or after platinum-based therapies.
[ad_2]
Source link
© Reuters. Why Novocure stock is up today?
NovoCure (NASDAQ:) experienced a notable increase in its stock price, jumping up around 13% intra-day today, marking its highest point since Oct 19. This boost is attributed to Novocure’s confirmation of its attendance at the upcoming JPMorgan healthcare investor conference next month. William Doyle, the Executive Chairman of Novocure, is scheduled to present on behalf of the company on Jan 10.
Earlier this month, Piper Sandler highlighted Novocure as one of the companies expected to share insights into their fourth-quarter performance at this annual health event. This expectation stems from Novocure’s history of providing such details in previous years.
Novocure, the maker of a wearable cancer-targeting therapy known as TTFields, announced last month a workforce reduction of 13%. Despite this, the company maintains its readiness for the potential approval of its treatment for metastatic non-small cell lung cancer after progression on or after platinum-based therapies.
About The Author
